An ABO-incompatible term infant girl born to parents who are Jehovah's Witnesses was admitted to our neonatal unit with a high serum bilirubin level necessitating exchange transfusion. The parents signed a request that blood should not be administered under any circumstances. However, they authorized us to apply the possible alternative treatments of orally administered D-penicillamine (300 mg/kg per day divided in three doses for 3 days), phototherapy, intravenous fluids, and recombinant human erythropoietin (200 U/kg subcutaneously on every second day for 2 weeks). Herein, we report the outcome of this baby, who was discharged from the our unit in good condition after treatment. Her physical growth and motor milestones at 14 months of age revealed no red flags for neurodevelopmental maturation. To our knowledge, this is the first case of an infant who received such a combined alternative (and "bloodless") treatment of serious ABO hemolytic disease of the newborn.
Erythroblastosis due to Rh incompatibility decreases in frequency following the successful anti-D-prevention of maternal isoimmunization; thus, pediatricians are giving more attention to ABO hemolytic disease of the newborn (ABO-HDN), which is the most common cause of antibody-induced neonatal hemolysis seen at present in newborns. Although most cases of ABO hemolysis are mild, severe cases with early and profound jaundice leading to kernicterus have been reported. 1 On occasion, hemolysis due to ABO incompatibility may also produce a postnatal anemia that is severe enough to require treatment (i.e., blood transfusion(s)).
In the early 1970s, when one of us (L. L.) reviewed the role of D-penicillamine (DPA) in the treatment of neonatal hyperbilirubinemia, the drug was new to most neonatologists.
2 DPA (␤,␤-dimethylcysteine), when given orally or intravenously to newborns, significantly reduces the plasma bilirubin concentration or prevents the increase usually seen during the first few days of life. 3 This treatment is especially effective in jaundice of hemolytic origin, such as ABO incompatibility, 4 and is used together with phototherapy 5 in several Hungarian clinics, where it has largely replaced exchange transfusions. Subsequently, this chelating agent proved to be effective in the prevention of retinopathy of prematurity 6,7 as well. Basic pharmacologic/pharmacokinetic data for this drug can be found in a review written by Rangachari and Kean. 8 In general, the Jehovah's Witness population constitutes a group of patients at high risk for morbidity and mortality associated with blood loss or hemolysis because of their refusal, on religious grounds, to accept transfusions or blood products based on their interpretation of biblical mandates. 9 For this reason, they provide a considerable challenge for caregivers. Children further complicate the situation in a medicolegal sense because, ordinarily, medical treatment to a minor child is administered only after informed consent has been obtained from the parent or guardian.
In this article, we will report a case of infant of the Jehovah's Witness faith suffering from ABO-HDN and treated with a "bloodless," combined alternative regime during her first weeks of life.
CASE REPORT
We recently cared for a term infant girl who was born at 39 weeks' gestation to a 24-year-old, blood group O, Rh-positive mother. The pregnancy was uncomplicated, and the group A, Rh-positive baby weighed 3100 gm. After delivery, she was in the well-baby nursery, was breast-feeding, and was nursing well; therefore, the direct Coombs test was not performed. The baby appeared jaundiced at 32 hours of life, and her serum bilirubin level was 170 mol/liter (9.95 mg/dl). The measurement of serum bilirubin concentration was repeated at 38 hours of age and showed a level of 290 mol/liter. Phototherapy was started, but this treatment was unable to stop the rapid increase in the bilirubin concentration. At 50 hours of age, the bilirubin level was 416 mol/liter (24.3 mg/dl); the hemoglobin value was 130 g/liter. The baby was transferred to our neonatal unit, and we decided to perform an exchange transfusion. At the time of admission the parents, belonging to the Jehovah's Witness sect, signed a request in the chart expressing their wish that blood not be administered under any circumstances. However, they authorized us to apply the alternative therapies of orally administered DPA (300 mg/kg per day, divided in three doses for 3 days), phototherapy, intravenous fluids, and recombinant human erythropoietin. The latter was started on day 7 at 200 U/kg subcutaneously and was given on every second day until day 23, supplemented with vitamin E, folic acid, and iron. The clinical characteristics of the infant with ABO-HDN are shown in Table 1 . Her physical growth and developmental processes at 14 months of age revealed no abnormalities of neurodevelopmental maturation, as International Perspective
based on an evaluation of (1) motor developmental milestones, (2) data obtained by the classic neurologic examination, and (3) cerebral neuromotor maturational markers, 10 the developmental quotient proved to be Ͼ100. In addition, the follow-up audiometric tests performed on this infant were normal.
COMMENTS
Our decision to abide by the parents' request to limit our therapy by withholding the use of transfusions was based three considerations. First, the baby's life was in no immediate danger and alternative treatments were available. Second, even at the highest bilirubin level, no symptoms or signs of central nervous system damage were observed. Third, the risk of the exchange transfusion itself is about 3 deaths per 1000 procedures; 11 there is always a risk of AIDS and hepatitis from transfusion, although it is now very low. Furthermore, we have had extensive experience with DPA therapy in the newborn and have not found it to be associated with either short-or long-term adverse effects, [12] [13] [14] although side effects of long-term oral DPA therapy, which is used for rheumatoid arthritis, Wilson's disease, and cystinuria, have been reported. Many of these are similar to autoimmune disorders and include membranous glomerulonephritis, lupus erythematosis (or similar skin eruptions), Goodpasture syndrome, drug fever, myasthenia gravis, polymyositis, aplastic anemia, thrombocytopenia, and agranulocytosis. Drosos et al. 15 have reported a strong association of such side effects with circulating cryoglobulin or autoantibodies in rheumatoid arthritis patients. Infants born following in utero exposure have been reported with connective tissue disruption, poor wound healing, or cutis laxa, although most pregnancies exposed to DPA have normal outcomes. 16 It is also interesting that copper metabolism in Wilson's disease and in newborn infants is strikingly similar. Both have large quantities of copper in the liver in contrast to an unusually low ceruloplasmin level in the blood. 17 Administration of the copper-chelating agent DPA leads to a clinical improvement in hepatolenticular degeneration without common toxic effects. It is worth mentioning that there is a conspicuous resemblance between our recent case and the first patient (K. E.) who received DPA treatment in the neonatal period 25 years ago. This girl was an ABO-incompatible preterm infant whose birth weight was 2200 gm. On day 2 of life, an exchange transfusion was required; however, not even this intervention was able to stop the rapid increase in the bilirubin level. At the beginning of the second exchange, cardiopulmonary arrest occurred requiring resuscitation. At an extremely high bilirubin level (32.5 mg/dl), intravenous administration of DPA was begun. The first dose caused a spectacular fall of 6.5 mg/dl in the level in 4 hours; under the influence of such treatment, we were able to witness a gradual disappearance of the hyperbilirubinemia. 2 K. E. is now an opera singer at the Wiesbaden Opera House (Germany). As far as the mechanisms of action of DPA in ABO-HDN are concerned, it proved to be a potent inhibitor of heme oxygenase, the rate-limiting enzyme in heme catabolism to bile pigments, only in the neonates. 18 Therefore, this drug can moderate the postnatal rate of increase of plasma bilirubin levels. The use of DPA in combination with phototherapy seems to be an apt combination to diminish the intensity of hyperbilirubinemia, because DPA decreases bilirubin production; simultaneously, by its antioxidant effects, 19 -21 DPA is able to prevent the possible adverse side effects of phototherapy that have been demonstrated in vitro and most recently in vivo. 22 Although this combined treatment of hyperbilirubinemia has been performed successfully in our case concerning the avoidance of an exchange transfusion in the infant with hemolytic disease, care must be taken not to overlook developing anemia, which may require transfusion. Recombinant human erythropoietin has been widely used for the treatment or prevention of the anemia of prematurity and of the late anemia due to Rh hemolytic disease of the newborn, as an alternative treatment to blood transfusion. [23] [24] [25] Table  1 shows that the baby's lowest hemoglobin level was 87 g/liter on day 12 and 120 g/liter on day 25, clarifying the existence of a serious hemolytic process and the efficacy of recombinant human erythropoietin administration.
Finally, we would like to emphasize that the combined alternative (and bloodless) treatment of ABO-HDN described herein may be an option in the Jehovah's Witness population and may benefit others as well. It should also be noted that, to our knowledge, this is the first baby who received the aforementioned therapy according to the medical literature. 
